Literature DB >> 33745927

The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia.

Weijia Yu1, Christoph Lutz2, Alwin Krämer3, Marion S Schmidt-Zachmann4.   

Abstract

As epigenetic regulators are frequently dysregulated in acute myeloid leukemia (AML) we determined expression levels of the JmjC-protein NO66 in AML cell lines and sub fractions of healthy human hematopoietic cells. NO66 is absent in the AML cell lines KG1/KG1a which consist of cells with the immature CD34+/CD38- phenotype and is regarded as a "stem cell-like" model system. Similarly, NO66 is not detectable in CD34+/CD38- cells purified from healthy donors but is clearly expressed in the more committed CD34+/CD38+ cell population. Loss of NO66 expression in KG1/KG1a cells is due to hyper-methylation of its promoter and is released by DNA-methyltransferase inhibitors. In KG1a cells stably expressing exogenous wild type (KG1a66wt) or enzymatically inactive mutant (KG1a66mut) NO66, respectively, the wild type protein inhibited proliferation and rDNA transcription. Gene expression profiling revealed that the expression of NO66 induces a transcriptional program enriched for genes with roles in proliferation and maturation (e.g.EPDR1, FCER1A, CD247, MYCN, SNORD13). Genes important for the maintenance of stem cell properties are downregulated (e.g. SIRPA, Lin28B, JAML). Our results indicate that NO66 induces lineage commitment towards myeloid progenitor cell fate and suggest that NO66 contributes to loss of stem cell properties.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Epigenetic modifiers; Hematopoietic stem cells; JmjC-proteins; NO66; Nucleolus; Ribosome biogenesis

Year:  2021        PMID: 33745927     DOI: 10.1016/j.yexcr.2021.112566

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  1 in total

1.  ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia.

Authors:  Omar S El-Masry; Ali M Alamri; Faisal Alzahrani; Khaldoon Alsamman
Journal:  Heliyon       Date:  2022-03-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.